Literature DB >> 7387762

Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man.

L Dei Cas, C Manca, G Vasini, M Mansour, B Bernardini, O Visioli.   

Abstract

An investigation on the effect of diisobutyric ester of N-methyl-dopamine (SB 7505) on systolic time intervals (STI), heart rate (HR), systolic arterial pressure (SAP), diastolic arterial pressure(DAP), saluretic activity was carried out on 8 male volunteer in-patients who had normal renal, gastrointestinal, cardiac and hepatic functions and were free from other serious illness. SB 7505 was administered orally at three doses of 50, 100 and 150 mg. HR, SAP and DAP either showed no variations or marginal insignificant shifts. STI decreased evidencing a dose-related positive inotropic effect like digitalis, but shorter than digitalis. SB 7505 also showed diuretic action with all three doses investigated. The positive inotropic effect and diuretic activity point to the possible usefulness of SB 7505 in treating some heart and kidney diseases.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387762

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

Review 1.  Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  J M Henwood; P A Todd
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Effect of ibopamine on heart rate and spontaneous premature ventricular beats in patients with angina pectoris.

Authors:  E Montani; M O Triulzi; G C Maggi
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Renal effect of SB 7505: a double-blind study.

Authors:  G F Melloni; G M Minoja; G Scorazzati; R Bauer; B Brusoni; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

4.  Clinical tolerability of ibopamine hydrochloride (SB 7505).

Authors:  G F Melloni; R Melloni; G M Minoja; G Scarazzati; G C Bruni; P Loreti; R Bauer
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Effect of ibopamine on peripheral haemodynamics.

Authors:  C Longhini; G F Musacci; L Ansani; T Toselli; M Artioli; L Bianco; P Ghirardi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Haemodynamic evaluation of ibopamine in severe congestive heart failure.

Authors:  G C Reffo; M Turrin; A Gabellini; C Forattini
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Authors:  P Ghirardi; B Brusoni; M Mangiavacchi; L Bianco; J Col; M Metra; L Dei Cas
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

8.  Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment.

Authors:  J Col; E Mievis; M Reynaert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report.

Authors:  S Stefoni; L Colì; G Mosconi; R Prandini
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

Review 10.  Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.

Authors:  C Spencer; D Faulds; A Fitton
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.